For Healthcare Professionals

A Study of WVT078 in Patients With Multiple Myeloma (MM)


About the study

The design of a phase I, open-label, dose finding study was chosen in order to establish a safe and tolerated dose of single agent WVT078 alone and in combination with WHG626 in patients relapses and/or refractory Multiple Myeloma (MM)

Who can take part

You may be eligible to participate in the study if you meet the following criteria:


Inclusion Criteria:

Subjects who are relapsed and/or refractory to two or more regimens including an IMID, proteasome inhibitor, and an anti-CD38 agent (if available)


Exclusion Criteria:

  1. Use of systemic chronic steroid therapy (>or= 10mg/day prednisone or equivalent) or any immunosuppressive therapy within 7 days of first dose of study treatment
  2. Malignant disease other than being treated on this study
  3. Active known or suspected autoimmune disease
  4. Impaired cardiac function or clinically significant cardiac disease
  5. Treatment with cytotoxic or small molecule antineoplastics or any experimental therapy within 14 days or 5 half-lives whichever is shorter
  6. Active central nervous system involvement by malignancy or presence of symptomatic CNS metasteses

pin location

Study Locations

Enter your ZIP code/Postal code/PIN code to locate study sites near you:

How to Apply

Contact the study center to learn if this study is a good match for you.

Study’s details


Multiple Myeloma (MM)

Age (in years)

18 - 99


Phase 1

Participants needed


Est. Completion Date

Sep 16, 2024

Treatment type



Novartis identifier


Study number


Understanding Clinical Trials

Get answers to your questions about clinical trials.What is a clinical research?What does taking part in clinical trials involve?What should I ask the trial doctor?


Sign up to save your favorites, 
receive newsletters, resources, and alerts 
about clinical trials related to your conditions of interest.